Summary:

- The article discusses a new experimental drug called gantenerumab, which is being investigated as a potential treatment for Alzheimer's disease.
- Gantenerumab is a monoclonal antibody that targets and removes the amyloid-beta protein, which is believed to be a key driver of Alzheimer's disease.
- The drug is currently being evaluated in a large-scale clinical trial involving individuals with a genetic predisposition to Alzheimer's, as early intervention may be crucial for the effectiveness of this type of treatment.